Zomedica Corp. Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin & Folate Assay

Reuters

2025/09/23

<a href="https://laohu8.com/S/ZOMDF">Zomedica Corp.</a> Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin & Folate Assay

Zomedica Corp. has announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin & folate assay. Initially launched in early 2024 for canine use, this multiplexed assay combines two critical tests in one, allowing veterinarians to perform in-clinic testing for cobalamin and folate, which are essential in diagnosing gastrointestinal conditions. The expansion now enables testing for feline patients, addressing a significant clinical need for timely and accurate results. This advancement allows for the assessment of two important biomarkers at the point of care, delivering reference-lab quality results in under 25 minutes. The addition of feline testing capability to the TRUFORMA platform provides veterinarians with improved diagnostic efficiency and supports enhanced clinical outcomes for feline patients. Results of this new capability were announced at the time of the platform's expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076864) on September 23, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569579791"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569579791\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569579791?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569579791","market":"us","top_or_hot":-1,"title":"Zomedica Corp. Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin & Folate Assay","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZOMDF\">Zomedica Corp.</a> Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin &amp; Folate Assay\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zomedica Corp. has announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin &amp; folate assay. Initially launched in early 2024 for canine use, this multiplexed assay combines two critical tests in one, allowing veterinarians to perform in-clinic testing for cobalamin and folate, which are essential in diagnosing gastrointestinal conditions. The expansion now enables testing for feline patients, addressing a significant clinical need for timely and accurate results. This advancement allows for the assessment of two important biomarkers at the point of care, delivering reference-lab quality results in under 25 minutes. The addition of feline testing capability to the TRUFORMA platform provides veterinarians with improved diagnostic efficiency and supports enhanced clinical outcomes for feline patients. Results of this new capability were announced at the time of the platform's expansion.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076864) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zomedica Corp. Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin & Folate Assay</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZomedica Corp. Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin & Folate Assay\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-23 18:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZOMDF\">Zomedica Corp.</a> Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin &amp; Folate Assay\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zomedica Corp. has announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin &amp; folate assay. Initially launched in early 2024 for canine use, this multiplexed assay combines two critical tests in one, allowing veterinarians to perform in-clinic testing for cobalamin and folate, which are essential in diagnosing gastrointestinal conditions. The expansion now enables testing for feline patients, addressing a significant clinical need for timely and accurate results. This advancement allows for the assessment of two important biomarkers at the point of care, delivering reference-lab quality results in under 25 minutes. The addition of feline testing capability to the TRUFORMA platform provides veterinarians with improved diagnostic efficiency and supports enhanced clinical outcomes for feline patients. Results of this new capability were announced at the time of the platform's expansion.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076864) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZOMDF","symbol_name":"Zomedica Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL9NCfKJ:1","article_id":"2569579791","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569579791","pubTimestamp":1758623417,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zomedica Corp. has announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin & folate assay. Initially launched in early 2024 for canine use, this multiplexed assay combines two critical tests in one, allowing veterinarians to perform in-clinic testing for cobalamin and folate, which are essential in diagnosing gastrointestinal conditions. The expansion now enables testing for feline patients, addressing a significant clinical need for timely and accurate results. This advancement allows for the assessment of two important biomarkers at the point of care, delivering reference-lab quality results in under 25 minutes. The addition of feline testing capability to the TRUFORMA platform provides veterinarians with improved diagnostic efficiency and supports enhanced clinical outcomes for feline patients. Results of this new capability were announced at the time of the platform's expansion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZOMDF":"Zomedica Corp.","BK4082":"医疗保健设备"},"translate_title":"Zomedica Corp.通过猫科动物诊断扩展TRUFORMA平台，用于钴胺素和叶酸检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZOMDF":0.9},"content_text":"Zomedica Corp. Expands TRUFORMA Platform with Feline Diagnostics for Cobalamin & Folate Assay\n    \n\n        Zomedica Corp. has announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin & folate assay. Initially launched in early 2024 for canine use, this multiplexed assay combines two critical tests in one, allowing veterinarians to perform in-clinic testing for cobalamin and folate, which are essential in diagnosing gastrointestinal conditions. The expansion now enables testing for feline patients, addressing a significant clinical need for timely and accurate results. This advancement allows for the assessment of two important biomarkers at the point of care, delivering reference-lab quality results in under 25 minutes. The addition of feline testing capability to the TRUFORMA platform provides veterinarians with improved diagnostic efficiency and supports enhanced clinical outcomes for feline patients. Results of this new capability were announced at the time of the platform's expansion.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076864) on September 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}